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Epidermolysis bullosa simplex (EBS) is a mechano-bullous disorder characterized by intraepidermal blistering
within the basal keratinocytes as a result of trauma to the skin. As part of the DNA diagnostics program, our
laboratory has analyzed a cohort of 57 patients with the initial referral diagnosis of EBS. Among these patients, 18
were found to harbor heterozygous mutations in the keratin 5 or keratin 14 genes, KRT5 and KRT14, respectively,
whereas in 14 cases, the disease was associated with mutations in both alleles of the plectin gene. Among the
keratin mutations, 12 were distinct and six were novel, and in most cases there was no family history of a blistering
disease. Prenatal diagnosis of eight pregnancies with keratin gene mutations, at risk for EBS either because one of
the parents was affected (three cases) or history of a previously affected child as a result of a de novomutation (ﬁve
cases), predicted two fetuses being affected and six being normal. No recurrence of the de novo mutations in these
pregnancies was disclosed. Collectively, the data suggest that a significant number of cases diagnosed as EBS are
due to plectin mutations, and many cases result from de novo mutations in KRT5 and KRT14 genes. These ﬁndings
have implications for genetic counseling and prenatal diagnosis for EBS.
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Epidermolysis bullosa (EB), a group of heritable me-
chanobullous disorders, displays a spectrum of severity of
skin manifestations (Fine et al, 1999). EB is traditionally di-
vided into three broad categories based on the level of tis-
sue separation within the cutaneous basement membrane
zone (BMZ), as determined by diagnostic transmission
electron microscopy and/or immunoepitope mapping (Fine
et al, 2000). One of them is EB simplex (EBS), which is
characterized by tissue separation within the basal layer
of epidermis due to fragility of basal keratinocytes. In
junctional forms of EB tissue separation takes place within
the dermo-epidermal basement membrane, primarily at
the level of lamina lucida, whereas in dystrophic forms the
blistering occurs below the lamina densa within the upper
papillary dermis at the level of anchoring fibrils (Uitto and
Richard, 2004). The variability in the phenotypic presenta-
tion of EB is now known to reflect the presence of mutations
in ten different genes (Pulkkinen et al, 2002; Uitto and
Richard, 2004). The compartmentalized expression of the
affected genes within the cutaneous BMZ and in extracu-
taneous tissues, as well as the types and positions of the
mutations and their consequences at the mRNA and protein
levels, explain the tremendous variability in EB phenotype
(Uitto and Pulkkinen, 2001).
EBS is the most common subtype of EB, and epidemi-
ological data emanating from the US National Epidermolysis
Bullosa Registry have suggested that EBS accounts for at
least half of all cases of EB (Fine et al, 1999). Furthermore,
the relative incidence of EBS may be much higher than that
since a proportion of affected patients, most notably those
with mild blistering, do not come to the attention of phy-
sicians. Traditionally, EBS has been divided into subcate-
gories reflecting the clinical severity and the types and
distribution of the lesions. EBS Dowling–Meara, which
presents with generalized herpetiform groups of vesicles
or bullae, can be associated with early infant mortality
(Dowling and Meara, 1954). EBS Ko¨bner manifests with
generalized blistering (Ko¨bner, 1886), whereas EBS Weber–
Cockayne presents with localized blistering primarily on the
hands and feet (Cockayne, 1938). A rare subtype of EBS is
associated with mottled pigmentation (Fischer and Gedde-
Dahl, 1979). These four types of EBS are inherited in most
cases in an autosomal-dominant fashion. An autosomal-re-
cessive form of EB associated with late-onset muscular
dystrophy (EBS-MD) has been classified as EBS because
the blistering is intracellular within the basal keratinocytes.
Similarly, a rare autosomal-dominant variant of EBS, the so-
called Ogna type, harbors mutations in the plectin gene
(Koss-Harness et al, 2002). It should be noted, however,
that blistering in EBS-MD and EBS-Ogna is low at the level
of hemidesmosomes at the apical pole of keratinocytes (see
Uitto et al, 1996; Pfendner et al, 2005).
Abbreviations: BMZ, basement membrane zone; EBS, epidermo-
lysis bullosa simplex
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In the classic forms of EBS, the basal cells disintegrate
as a result of shearing trauma to the skin, and the cell fra-
gility is due to defective intermediate keratin filament net-
work resulting from mutations in the basal keratin genes,
KRT5 and KRT14 (Irvine and McLean, 1999; Cassidy et al,
2002; Rugg and Leigh, 2004). The majority of the cases
show autosomal-dominant inheritance, although rare au-
tosomal-recessive cases have been described (Hovnanian
et al, 1993; Batta et al, 2000). In addition, a number of cases
are sporadic with no family history of blistering diseases.
The DebRA Molecular Diagnostics Laboratory, located at
Jefferson Medical College, Philadelphia, Pennsylvania, has
provided DNA-based diagnostic services to the global EB
community since 1996. As of today, we have analyzed over
1000 families with different forms of EB, most with severe
recessive dystrophic or lethal junctional variants. Among the
families studied, there were 57 individuals referred to us
with the diagnosis of EBS. DNA analysis revealed specific
mutations either in KRT5 or KRT14 in 18 families (see be-
low). Careful examination of the remaining 39 cases reveals
that in 16 cases, the referral diagnosis of EBS was not
correct or was not consistent with electron microscopic
or immunofluorescence findings, whereas 14 cases were
found to harbor mutations in PLEC1 (see Pfendner et al,
2005). These observations reinforce the importance of good
histopathological, immunofluorescence, and ultrastructural
data prior to molecular genetic screening. In the remaining
nine cases, the electron microscopic and/or immunohisto-
chemical data supported the diagnosis of EBS, but no mu-
tations in the KRT5, KRT14, or plectin genes could be
identified in spite of extensive sequencing of the exons and
flanking introns. In the latter cases, it is possible that mu-
tations in these three candidate genes may exist in the re-
gions not examined by us for mutations, including the
promoter regions and intronic sequences beyond 100–200
bp away from the intron–exon junctions.
DNA was isolated from peripheral blood specimens, or in
case of the prenatal testing, from chorionic villus samples,
after a written informed consent was obtained from the pa-
tients or their guardians. The studies were approved by the
Institutional Review Board of Thomas Jefferson University,
and they adhere to the Declaration of Helsinki Principles.
PCR amplification of exons and flanking intronic sequences
of KRT5 and KRT14 (Whittock et al, 2000; Wood et al, 2003),
followed by direct dideoxide nucleotide sequencing, of the
probands’ DNA resulted in identification of heterozygous
keratin 5 or keratin 14 gene mutations in 18 families (Table I).
Twelve distinct mutations were disclosed, six of them pre-
viously unpublished. In seven cases, the mutations resided
in KRT5 and in eleven cases in KRT14, indicating that mu-
tations in either gene can result in EBS at an approximately
equal frequency. In 11 cases, DNA was available from both
parents, and in only three cases the corresponding mutation
was present in the peripheral blood DNA of one of the par-
ents (Table I). In seven families in which DNA samples were
not available from the parents, there was no family history of
a blistering skin disease, and specifically, the parents were
clinically unaffected. Based on this information, it appears
that a large number of cases in this cohort (15 of 18) may
represent de novo mutations in KRT5 or KRT14. It is likely,
however, that more severe cases and in particular those
who have no known family history are overrepresented
in this cohort, as these cases were referred to for genetic
evaluation at birth or shortly thereafter to clarify the mode of
inheritance.
Examination of the mutation database indicated that,
with the exception of one case (no. 16), the mutations were
missense substitutions primarily within the helix initiation or
termination peptides. A recurrent R125C mutation was en-
countered in three families, and the same arginine residue
was also mutated twice to histidine (R125H). The previously
reported mutation N123S was disclosed in four families.
Careful examination of the clinical features, as reported by
the referring physicians and summarized in Table I, revealed
that the recurrent mutation N123S appears to be associated
with severe generalized blistering with oral mucous mem-
brane involvement (EBS Dowling–Meara). In one case (no.
1), the severity of the airway involvement necessitated
tracheotomy. One case of EBS with palmoplantar kerato-
derma and mottled pigmentation harbored the P25L muta-
tion in KRT5 (no. 13), confirming previously reported
association of this particular mutation with the mottled pig-
mentation phenotype (Uttam et al, 1996; Nobuhara, 2003).
Finally, a single amino acid deletion (delI183) (no. 16), a
de novo event, resulted in generalized blistering but without
scarring (EBS Ko¨bner).
EBS has been considered to be a relatively mild disease;
however, our observations clearly indicate that EBS can be
severe. The more severe phenotype appears to be associ-
ated with certain mutations, such as N123S of KRT14. This
mutation resides within the 1A domain of the keratin mol-
ecule and is predicted to severely perturb the intermediate
filament network.
These observations clearly impact the genetic counsel-
ing of the families regarding the recurrence risk of EBS to
clinically normal parents with a previously affected child
with EBS. The extent of the risk for recurrence in each family
is variable, but estimates from other heritable diseases
suggest a range from 0.02% to 14% depending on the dis-
order (Byers et al, 1988; Bakker et al, 1989; Green et al,
1999; Mettler and Fraser, 2000). The a priori risk can be
determined from a general formula, in which there is only
one affected sibling in a family of otherwise untyped normal
siblings as between 1.6% and 4.8% (van der Meulen et al,
1995). For genetic counseling purposes, we quote an EBS
recurrence risk in a family of one affected offspring as be-
tween 2% and 5%, consistent with the calculated value. In
case of EB, the risk of recurrence is real, as has been doc-
umented by de novo cases with dystrophic or junctional EB
(Cserhalmi-Friedman et al, 2001, 2002).
As indicated above, the severity of EBS is highly variable,
but at one end of the spectrum, the disease can result,
although rarely, in premature demise of the affected indi-
viduals during the early postnatal period. In such cases,
prenatal diagnosis has been requested by the parents in
subsequent pregnancies (Rugg et al, 2000; Pfendner et al,
2003). We have performed DNA-based prenatal diagnosis in
eight EBS families with established keratin mutations (Table
II). In three cases (S1, S7, and S8), one of the parents was
affected with EBS, whereas in the remaining five cases the
parents were clinically normal but they had a previously af-
fected child with a de novo keratin mutation. Among the
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eight pregnancies tested, six were shown to have normal
genotype, whereas two (S1 and S7) were diagnosed to have
recurrence of dominant, paternally inherited disease. These
predictions were confirmed in six cases by the birth of a
healthy child. In case of the affected fetus in test S1, the
birth of an affected fetus was confirmed by clinical obser-
vations, whereas the case in test S7 was lost to follow-up. In
general, the most common reason given for the prenatal
test was the knowledge to prepare for an affected child.
Thus, prenatal testing in EBS is primarily used for counsel-
ing purposes rather than prevention.
Collectively, our data confirm that patients with an EBS
phenotype harbor a spectrum of mutations in the KRT5 or
KRT14 genes. Our results suggest a high rate of de novo
mutations, as the corresponding mutations were absent in
the parents’ peripheral blood cell DNA and/or there was no
family history of blistering diseases. Finally, we demonstrate
the feasibility of prenatal diagnosis for EBS in families at risk
for recurrence of the disease with phenotype of such se-
verity that prenatal testing is warranted in preparation for
the birth of an affected child.
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